Rize Oncology Inc.
CNSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 77.17% | -21.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -40.79% | -9.20% | |||
| Operating Income | 40.79% | 9.20% | |||
| Income Before Tax | 41.89% | 7.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 41.89% | 7.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 41.89% | 7.71% | |||
| EBIT | 40.79% | 9.20% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 44.90% | 7.55% | |||
| Normalized Basic EPS | 45.16% | 6.06% | |||
| EPS Diluted | 44.90% | 7.55% | |||
| Normalized Diluted EPS | 45.16% | 6.06% | |||
| Average Basic Shares Outstanding | 6.13% | 0.00% | |||
| Average Diluted Shares Outstanding | 6.13% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||